Methods to avoid adverse effect of circulating antigen on biodistribution of 125I-labeled antiTac dsFv: Preinjection of intact antibody versus clearance of antigen with avidin-biotin system

Journal of Nuclear Medicine

Volumn 40, Issue 8, 1999, Pages 1381-1391

  Kobayashi, Hisataka ^b   Bao Fu, Sun ^b   Yoo, Tae M ^b   Nhat, Le ^b   Meyoung Kon, Kim ^b   Paik, Chang H ^b   Pastan, Ira ^b   Waldmann, Thomas A ^b   Carrasquillo, Jorge A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

Avidin; Fv fragment; Interleukin 2; Monoclonal antibody; Radioimmunodetection

Indexed keywords

ANTIGEN; AVIDIN; IODINE 125; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

ANIMALS; ANTIBODIES, MONOCLONAL; AVIDIN; BIOTINYLATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IODINE RADIOISOTOPES; MICE; MICE, NUDE; RECEPTORS, INTERLEUKIN-2; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION;

EID: 0345425709     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Carrasquillo JA. Radioimmunotherapy of leukemia and lymphoma. In: Wagner H, ed. Principles of Nuclear Medicine. 2nd ed. Philadelphia, PA: WB Saunders;1996: 1117-1132.
2. Larson SM, Divgi CR, Scott AM. Overview of clinical radioimmunodetection of human tumors. Cancer. 1994;73:832-835.
3. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122:467-481.
4. Johnson VG, Schlom J, Paterson AJ, Bennett J, Magnani JL, Colcher D. Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res. 1986;46:850-857.
5. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med. 1990;113:619-627.
6. Junghans RP, Carrasquillo JA, Waldmann TA. Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies. Proc Natl Acad Sci USA. 1998;95:1752-1757.
7. Pimm MV. Circulating antigen: bad or good for immunoscintigraphy? Nucl Med Biol. 1995;22:137-145.
8. Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86:4063-4075.
9. 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res. 1990;50:1022s-1028s.
10. Huston JS, Mudgett-Hunter M, Tai MS, et al. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol. 1991;203:46-88.
11. Webber KO, Kreitman RJ, Pastan I. Rapid and specific uptake of anti-Tac disulfide-stabilized Fv by interleukin-2 receptor-bearing tumors. Cancer Res. 1995;55:318-323.
12. 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the α subunit of interleukin-2 receptor in the circulation with preinjected humanized anti-Tac IgG. Cancer Res. 1997;57:1955-1961.
13. Berson SA, Yalow RS. Insulin in blood and insulin antibodies. Am J Med. 1966;40:676-690.
14. Waldmann TA, Pastan IH, Gansow OA, Junghans RP. The multichain interleukin-2 receptor: a target for immunotherapy. Ann Intern Med. 1992;116:148-160.
15. Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988;31:729-735.
16. Nakanishi K, Taniguchi Y, Ohta Y. Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease. Acta Endocrinol (Copenh). 1991;125:253-258.
17. Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981;126:1393-1397.
18. Parenteau GL, Dirbas FM, Garmestani K, et al. Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimulating factor. Transplantation. 1992;54:963-968.
19. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med. 1998;338:161-165.
20. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987;28:1294-1302.
21. Goodwin DA, Meares CF. Pretargeting: general principles; October 10-12, 1996. Cancer. 1997;80:2675-2680.
22. Casalini P, Luison E, Menard S, Colnaghi MI, Paganelli G, Canevari S. Tumor pretargeting: role of avidin/streptavidin on monoclonal antibody internalization. J Nucl Med. 1997;38:1378-1381.
23. Sharkey RM, Karacay H, Griffiths GL, et al. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug Chem. 1997;8:595-604.
24. Kobayashi H, Sakahara H, Hosono M, et al. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a chase without decreased accumulation in the target tumor. J Nucl Med. 1994;35:1677-1684.
25. Paganelli G, Stella M, Zito F, et al. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. J Nucl Med 1994;35:1970-1975.
26. Webber KO, Reiter Y, Brinkmann U, Kreitman R, Pastan I. Preparation and characterization of a disulfide-stabilized Fv fragment of the anti-Tac antibody: comparison with its single-chain analog. Mol Immunol. 1995;32:249-258.
27. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA. 1989;86:10029-10033.
28. Green NM. Avidin. Adv Protein Chem. 1975;29:85-133.
29. Kobayashi H, Sakahara H, Endo K, Yao ZS, Toyama S, Konishi J. Repeating the avidin chase markedly improved the biodistribution of radiolabelled biotinylated antibodies and promoted the excretion of additional background radioactivity. Eur J Cancer. 1995;31A:1689-1696.
30. Fraker PJ, Speck JC Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3α,6α-diphrenylglycoluril. Biochem Biophys Res Commun. 1978;80:849-857.
31. 212Bi-anti-Tac. Cancer Res. 1994;54:4362-4370.
32. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89.
33. 99mTc-labeled anti-Tac dsFv. Cancer Res. 1996;56:3788-3795.
34. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. 1995;55:3825-3834.
35. 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen. Jpn J Cancer Res. 1998;89:436-444.
36. Junghans RP, Waldmann TA. Metabolism of Tac (IL2Rα): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med. 1996;183:1587-1602.
37. Yu B, Carrasquillo J, Milenic D, et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol. 1996;14:1798-1809.
38. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402-3408.
39. 125I-labeled des(1-3) insulin-like growth factor I in tumor-bearing nude mice and its in vitro catabolism. Cancer Res. 1997;57:2754-2759.
40. Chinol M, Casalini P, Maggiolo M, et al. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br J Cancer. 1998;78:189-197.